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INTRODUCTION
Fibromyalgia (FM) is a common, chronic widespread pain
disorder that is estimated to impact 0.5% to 7% of the gen-
eral population worldwide (Balon and Wise, 2015). The
epidemiology of FM in Latvia has not been studied in de-
tail.
Host individuals diagnosed in clinics are young or middle
aged; however, population surveys suggest that frequency
of disease increases with age as well as symptom severity
and worsening of life quality (Ballantyne et al., 2010;
Branco et al., 2010; Jiao et al., 2014; Balon and Wise,
2015). Females suffer from FM eight times more frequently
than males (Albin et al., 2008).
The term fibromyalgia appeared relatively recently, in 1976.
Diagnosis is clinical and is based on the 1990 American
College of Rheumatology (ACR) diagnostic criteria. Ac-
cording to these criteria, FM diagnosis may be stated if the
patient has chronic widespread pain and 11 or more positive
of a possible 18 tender points on physical examination, fa-
tigue, sleep disorders, headaches, memory or concentration
problems, mood disturbances, and stiffness.
In 2010, ACR FM diagnostic criteria were supplemented
with new details (Hakim et al., 2010; Wolfe et al., 2011)
that include the estimation of the widespread pain index
(WPI) and the symptoms of severity (SS) score scale. The
SS scale score is the sum of the severity of three symptoms
(fatigue, waking unrefreshed, cognitive symptoms) plus the
extent of somatic symptoms in general.
The aetiology and pathogenesis of FM are still unknown.
This disease is probably of multi-factorial nature, since
many patients have onset of the clinical phenotype of FM
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Fibromyalgia (FM) is a chronic widespread pain disorder that impacts 0.5%–7% of the general
population worldwide. The aetiology and pathogenesis of the disease are still unknown. Human
herpesvirus-6 and -7 belong to the family Herpesviridae, subfamily Betaherpesvirinae, and genus
Roseolovirus and are immunomodulating viruses potentially pathogenic to the nervous system.
Presence of anti-HHV-6 and -HHV-7 antibodies and viral genomic sequences, viral loads, HHV-6
variant-specificity, and TNF- level were studied in 41 FM patients and 50 healthy individuals us-
ing polymerase chain reactions, restriction endonuclease analysis and ELISA. There was no dif-
ference in the presence of anti-HHV-6 and anti-HHV-7 IgG class antibodies between FM patients
and control group individuals. Viral sequences were found in 80.5% of FM patients and in 62.0%
of controls. Significantly higher rate of concurrent HHV-6 and HHV-7 infection and higher viral
loads in peripheral blood were detected in FM patients compared to the control group individuals.
Plasma viremia was detected only in FM patients. Significantly higher TNF- levels were detected
in virus positive FM patients. From all positive cases only in two FM patients HHV-6A was re-
vealed. Significantly higher detection frequency of concurrent HHV-6 and HHV-7 infection, simul-
taneous HHV-6 and HHV-7 activation, higher viral loads and TNF- expression levels in primary
FM patients than in control group individuals indicate the potential involvement of Roseoloviruses
in development of this disorder.
Key words: fibromyalgia, human herpesvirus-6, human herpesvirus-7, infection, molecular diag-
nostic.
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following a specific trigger. There are many open questions
with few or controversial answers. Such triggers can include
various viral infections, such as hepatitis C (Kozanoglu et
al., 2003; Mohammad et al., 2012; Rogal et al., 2015), par-
vovirus B19 (Cassisi et al., 2011), HIV (Kole et al., 2013;
Wiffen et al., 2013; Fox and Walker-Bone, 2015), and Ep-
stein-Barr virus (Buchwald et al., 1987). 55% of patients
identify a “flu-like” or viral infection as a precursor to the
onset of symptoms, but the role of viral infection in FM de-
velopment has not been estimated.
One of the major theories is that cytokines may have a role
in both the aetiology of the FM and in the intensity of core
symptoms (Menzies and Lion, 2010). Goldberg (1989) sug-
gests that the viruses might directly invade central nervous
system or are capable of activating cytokines which may in
turn cause severe myalgia, fatigue, and neurocognitive dis-
turbances.
According to the current state of knowledge the origin of
the pain in FM and variety of FM symptoms are triggered
by peripheral as well as central mechanisms (Sprott, 2011;
Clauw et al., 2011).
Up to date, there are no data on the role of HHV-6 and
HHV-7 infection in the FM development. Human herpes-
virus-6 (HHV-6) and -7 (HHV-7) belong to the Herpesviri-
dae family, Betaherpesvirinae subfamily, Roseolovirus ge-
nus (Berneman et al., 1992) and are ubiquitous (more than
90% of adults have antibodies to the viruses) immunomodu-
lating, and potentially pathogenic to the nervous system. In
2012, the International Committee on Taxonomy of Viruses
re-classified HHV-6 as separate viruses HHV-6A and
HHV-6B based on biocharacteristics regarding cell tropism
and pathological implications (Ablashi et al., 2014). After
primary infection, the viruses establish a state of life-long
subclinical persistence or latency in CNS (Yoshikawa and
Asano, 2000) and can be reactivated in cases of immuno-
suppression. HHV-6A, HHV-6B and HHV-7 DNA are of-
ten found in brain tissue from healthy individuals (without
pathological changes in the brain) (Chan et al., 2001; Yao et
al., 2010).
HHV-6 infection has been associated with neurologic pa-
thologies such as multiple sclerosis (Ablashi et al., 2000;
Chapenko et al., 2003; Nora-Krukle et al., 2011), which is
associated with inflammation, mesial temporal lobe epi-
lepsy in the absence of inflammation in brain tissue (Donati
et al., 2003; Fotheringham et al., 2007; Niehusmann et al.,
2010), myalgic encephalomyelitis/chronic fatigue syndrome
(Ablashi et al., 2000; Chapenko et al., 2006; Bansal et al.,
2012; Chapenko et al., 2012) and with different neurologi-
cal complications after allogeneic hematopoietic stem cell
transplantation (Bhanushali et al., 2013) and solid organ
transplantations (Chapenko et al., 2009; Massih and Ra-
zonable, 2009). The association of HHV-7 infection with
these disorders is not sufficiently studied.
HHV-6 and HHV-7 infection profoundly modifies the pro-
file of cytokine and chemokine production, which in turn
may significantly affect the generation and functionality of
effective immune responses (Lusso et al., 2006). Lusso
(2006) and Atedzoe et al. (1999) have shown that both of
the viruses increase the production of inflammatory cytoki-
nes.
The aim of this study was to: 1) examine the presence of
HHV-6 and/or HHV-7 genomic sequences in whole periph-
eral blood and cell free plasma DNA samples from patients
with FM and practically healthy persons (control group);
2) determine HHV-6 variant-specificity in whole peripheral
blood DNA; 3) compare HHV-6 and HHV-7 load in periph-
eral blood samples from the FM patients and control per-
sons; 4) compare pro-inflammatory cytokine TNF- plasma
level in patients with FM and control group individuals.
MATERIALS AND METHODS
The study was performed during 2013–2015. Clinical and
virological (including serology and molecular biology) fea-
tures were examined in the 41 patients with clinical diag-
nose of primary FM and 50 practically healthy persons. The
primary FM diagnosis was established by a neurologist or
algologist in the out-patients’ clinic of Pauls Stradiòð Clini-
cal University Hospital. None of the 41 patients with pri-
mary diagnosed FM were hospitalised in the Neurology and
Neurosurgery Hospital. According to case and drug history,
10 of the 41 patients had not received prior medical treat-
ment; none of the patients had received steroids or statins,
but pain relief medication only.
Diagnosis was setup based on ACR 2010 diagnostic criteria
for the FM (Widespread pain index (WPI) is equal or more
than 7, symptom severity scale score (SS) — equal or more
than 5, duration of symptoms at least three months, and the
patients do not have a disorder that would otherwise explain
the pain). In our FM patients group the mean WPI was 12.7
± 3.24 (minimal score 4 and maximal score 18), and mean
SS scale score — 8.1 ± 1.4 (minimal score 6 and maximal
score 11). Mean duration of symptoms was 7.9 ± 6.2 years.
Exclusion criteria were previously known polyneuropathy,
cervical radiculopathy clinical symptoms, diabetes mellitus,
rheumatoid arthritis, liver diseases, myalgic encephalomye-
litis/chronic fatigue syndrome, and myocardial infarction.
Of 41 individuals with FM, 40 were females and one was
male (mean age 51, range: 24–71) and from 50 control
group individuals, 40 were females and 10 were males
(mean age 48, range: 35–78). Peripheral blood samples
from the patients with FM were received from the Neurol-
ogy and Neurosurgery Department, Rîga Stradiòð Univer-
sity.
The study was approved by the Ethics Committee of Rîga
Stradiòð University, and all of the participants gave in-
formed consent before the examination.
HHV-6 and HHV-7 serology. Testing for antibodies
against HHV-6 and HHV-7 in cell free blood plasma sam-
ples was carried out using HHV-6 IgG ELISA kits (Panbio,
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Sinnamon Park, QLD, Australia) and HHV-7 IgG ELISA
kits (ABI, Columbia MD, ASV) in accordance with the
manufacturer’s recommendations.
Nested polymerase chain reaction (nPCR). The technique
of nPCR was used for the detection of viral genomic se-
quences in DNA isolated from whole peripheral blood
(WPB) and cell free blood plasma. Total DNA was isolated
from WPB using standard phenol-chloroform extraction.
The QIAamp DNA Blood Mini Kit was used to extract
DNA from plasma. To assure the quality of the DNA, a
-globin PCR was performed. PCR amplification for the vi-
ruses was carried out in the presence of 1 µg WPB DNA
and 10 µl plasma DNA (corresponding to 100 µl plasma).
HHV-6 and HHV-7 DNA were detected in accordance with
Secchiero et al. (1995) and Berneman et al. (1992), respec-
tively. Positive controls (HHV-6 and HHV-7 genomic
DNA; ABI, Columbia, MD, USA) and negative controls
(DNA obtained from practically healthy HHV-6 and
HHV-7 negative donors and reaction without template
DNA), as well as water controls were included in each ex-
periment.
Restriction endonuclease analysis. Restriction endonucle-
ase analysis was carried out using enzyme HindIII (Thermo
Scientific, USA) which cleaves HHV-6B 163bp amplimer
into two fragments: 66 and 97 bp and does not cleave
HHV-6A amplimer (Secchiero et al., 1995).
Quantitative real-time polymerase chain reaction.
HHV-6 load was detected in all positive (according to
nPCR data) for viral DNA WPB samples from the patients
with FM and controls group individuals using a HHV-6
Real-TM Quant kit (Sacace, Biotechnologies, Italy) and Ap-
plied Biosystems 7500 Real-time PCR System (Applied
Biosystems, USA), according to the manufacturer's recom-
mendations. The test sensitivity corresponded to five copies
of the HHV-6 DNA per 105 cells. HHV-7 load was detected
in all positive (according to nPCR data) for viral DNA sam-
ples from the patients with FM and controls group individu-
als using Quantification of Human Herpes Virus 7 genomes
Major Capsid Protein (U57) (PrimerDesignTM Ltd, genesig
detection kits). The test sensitivity is not indicated.
Assay for cytokine determinations. A TNF- ELISA kit
(Biorbyt) was used for TNF- detection in plasma samples
from the FM patients with persistent infection in latent
phase and active phase, and without viral infection. The
sensitivity of the ELISA assay was < 1 pg/ml. All samples
were tested in duplicate.
Statistical analysis. Statistical differences in the detection
frequency of HHV-6 and/or HHV-7 genomic sequences in
the DNA samples from WPB of the individuals with FM as
well as the control group persons were assessed with the
Fisher’s exact test. The plasma cytokine level (TNF-) was
expressed as mean ± SD. SPSS software was used to assess
the continuous variable values of cytokine level with a
value of p < 0.05 considered as significant.
RESULTS
Seroepidemiology. Specific anti-HHV-6 IgG class antibod-
ies were found in 85.4% (35/41) and specific anti-HHV-7
IgG class antibodies in 83.0% (34/44) of plasma samples
from patients with FM. No difference in the prevalence of
anti-HHV-6 and anti-HHV-7 IgG class antibodies between
FM patients and control group individuals was detected
(44/50, 88.0%, p > 0.05).
HHV-6 and/or HHV-7 genomic sequences in patients
with fibromyalgia. Roseolovirus genomic sequences were
detected in 80% (33/41) versus 62.0% (31/50) in control
group individuals (p = 0.067). The detection frequency of
single HHV-6, single HHV-7 and concurrent HHV-6+
HHV-7 genomic sequences in the FM patients and control
group individuals are summarized in Table 1.
No difference in the frequency of single HHV-6 and single
HHV-7 infection between FM patients and control group in-
dividuals was detected (p = 0.204). However, a significantly
higher detection rate of concurrent (HHV-6+HHV-7) infec-
tion markers was revealed in FM patients in comparison
with control group individuals (15/41, 36.6% vs 2/50, 4.0%,
respectively; p = 0.00008).
Plasma viremia (marker of active viral infection) was re-
vealed only in patients with FM (6/33, 18.2%). As shown in
the Table 1, HHV-6 genomic sequence in plasma DNAs
upon single HHV-6 persistent infection was detected in two
of three patients, simultaneous activation of both viruses
upon concurrent persistent infection in two of 15, and
HHV-7 genomic sequences in two out of 15 FM patients
with single HHV-7 persistent infection.
HHV-6 and HHV-7 load in whole peripheral blood.
Mean HHV-6 and HHV-7 load levels were higher in FM
patients compared to the healthy persons. The mean HHV-6
load in WPB of FM patients with persistent infection in la-
tent phase was 752.47 [range: 195.5–1129.8] copies/106
cells, compared to 125.5 [range: 52.5–192.5] copies/106
cells in the control group samples. Mean HHV-7 load was
218.3 [range: 132.0–311.0] copies/106 cells in WPB of FM
T a b l e 1
FREQUENCY OF HHV-6 AND HHV-7 GENOMIC SEQUENCES IN
WHOLE PERIPHERAL BLOOD (WPB) AND CELL FREE PLASMA
DNA FROM PATIENTS WITH FIBROMYALGIA (FM) AND CON-
TROL GROUP INDIVIDUALS BY nPCRa
Subjects
Viral genomic sequences
single HHV-6 single HHV-7 concurrent
HHV-6+HHV-7
WPB plasma WPB plasma WPB plasma
FM 3/41 2/3 15/41 2/15 15/41* 2/15
Control 3/50 0/3 26/50 0/26 2/50 0/2
a nPCR, nested polymerase chain reaction
* Significantly higher rate in FM patients versus control individuals (p <
0.001).
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patients with persistent infection in latent phase and 181.52
[range: 86.63–281.37] copies/106 cells in WPB of control
group individuals. Higher mean HHV-6 and HHV-7 loads
were detected in WPB of FM patients with plasma viremia
(5511.6 [range: 1108–21200] and 744.25 [range: 602.0–
1058] copies/106 cells, respectively).
TNF- level. To investigate the relationship between the
reactivation of HHV-6 and/or HHV-7 and changes in
plasma cytokine level, the level of pro-inflammatory
cytokine TNF- was measured in FM patients with persis-
tent infection in latent phase (27/41), FM patients with ac-
tive viral infection (6/41), and without viral infection (8/41).
The TNF- level was significantly higher in patients with
active viral infection (39.33 ± 35.50 pg/ml, p = 0.018) and
in those with persistent infection in latent phase (19.75 ±
8.84 pg/ml, p = 0.044) than in the patients without viral in-
fection (5.33 ± 1.53 pg/ml).
Determination of HHV-6 variant-specificity. HHV-6A
was identified in two and HHV-6B in 16 of 18 FM patients
positive for HHV-6 infection. HHV-6B was identified in all
control individuals.
DISCUSSION
Fibromyalgia (FM) is a chronic disorder that is part of a
spectrum of syndromes manifested by diffuse musculo-
skeletal pain and additional somatic symptoms like fatigue,
sleep, emotional disturbance, depression, cognitive symp-
toms, gastrointestinal symptoms, and headache. The disor-
der can have a devastating effect on peoples’ lives and also
imposes large economic burdens on society.
Although inflammatory, infectious, and autoimmune disor-
ders have all been ascribed to be aetiological events in the
development of FM, there is very little data to support such
a thesis (Borchers and Gershwin, 2015).
At present, clinical diagnostic criteria for FM has been
elaborated (Wolfe et al., 2010); however, the aetiology and
pathophysiology of the disease remains unclear (Albin et
al., 2008).
Up to date, no data exist on the role of HHV-6 and HHV-7
infection in FM development, although HHV-6 and HHV-7
are ubiquitous viruses with immunomodulating properties
and are potential pathogens to the nervous system (Lusso,
2006).
We investigated the detection frequency of single HHV-6,
single HHV-7 and concurrent HHV-6+HHV-7 genomic se-
quences in DNA samples isolated from WPB and cell-free
blood plasma from patients with clinically diagnosed FM
and control group subjects (Table 1). Although the results
of our study show no difference in the detection frequency
of single HHV-6 and single HHV-7 infection, the rate of
concurrent HHV-6+HHV-7 infection is significantly higher
in patients with FM than in healthy individuals (p =
0.00008). Active viral infection (plasma viremia) was de-
tected only in FM patients (18.2%).
Increase of mean HHV-6 and HHV-7 loads in WPB of FM
patients with persistent infection in latent phase as well as
with active infection, in comparison with control subjects,
was found.
We found limited empirical evidence to support the associa-
tion of increased pro-inflammatory cytokine levels with FM
development (Menzies and Lyon, 2010). Our results
showed that significantly higher TNF- level occurred in
FM patients with active viral infection as well as in patients
with persistent infection in latent phase, in comparison with
control group individuals. Taking into account the immuno-
modulating properties of these viruses, quantitative and
qualitative changes on system levels of cytokines in the pa-
tients with FM cannot be excluded.
At present, the question of potential interaction between
HHV-6 and HHV-7 in cases of concurrent infection is not
clear. Significantly frequent detection of concurrent infec-
tion and simultaneous activation of both viruses only in FM
patients allow to suggest the potential interaction between
these viruses as well as in development of FM. Our results
are in accordance with previous in vitro (Katsafanas et al.,
1996; Tanaka-Taya et al., 2000) and in vivo (Boutolleau et
al., 2003; Hall et al., 2006) studies.
More frequent detection of HHV-6B in FM patients and
healthy individuals indicates that either HHV-6A occurs in-
frequently in these individuals or that there is a difference in
HHV-6A and HHV-6B geographical distribution and the
HHV-6B in our area is predominant (Boutolleau et al.,
2006; Bates et al., 2009).
CONCLUSION
Significantly higher detection frequency of concurrent
HHV-6 and HHV-7 infection, simultaneous HHV-6 and
HHV-7 activation, higher HHV-6 and HHV-7 load, as well
as increased expression level of TNF- in patients with FM,
in comparison with control group individuals, indicate a po-
tential association of roseolovirus infection with primary
fibromyalgia
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IESPÇJAMÂ ROSEOLOVÎRUSU INFEKCIJAS SAISTÎBA AR FIBROMIALÌIJU
Fibromialìija (FM) ir izplatîta hroniska slimîba, kas izraisa sâpes, pasliktina dzîves kvalitâti un samazina dzîvildzi. Tâ skar 0.5% lîdz 7% no
visas pasaules iedzîvotâju populâcijas. Slimîbas etioloìija un patoìençze ðobrîd nav pilnîbâ skaidra. Cilvçka herpesvîruss-6 (HHV-6) un -7
(HHV-7) ir nervu sistçmas potenciâlie patogçni. HHV-6 un HHV-7 antivielu klâtbûtne, HHV-6 un/vai HHV-7 infekcijas izplatîba, vîrusa
slodze, HHV-6 varianta specifiskums un TNF- ekspresijas lîmenis tika noteikts 41 pacientam ar fibromialìiju un 50 praktiski veseliem
indivîdiem, izmantojot polimerâzes íçdes reakciju, restrikcijas endonukleâzes analîzi un ELISA. 85.4% FM pacientu tika atrastas
anti-HHV-6 IgG klases antivielas un 83.0% — anti-HHV-7 IgG klases antivielas. Roseolovîrusu genoma secîbu klâtbûtne atrasta 80.5%
FM pacientu un 62.0% praktiski veselu indivîdu. Vienlaicîga HHV-6+HHV-7 genomu secîbu klâtbûtne bûtiski bieþâk konstatçta FM
pacientiem. Plazmas virçmija (aktîvas infekcijas maríieris) konstatçta tikai FM pacientiem. HHV-6 un HHV-7 slodze perifçro asiòu DNS
paraugos visaugstâkâ bija FM pacientiem ar aktîvu vîrusu infekciju, taèu arî FM pacientiem ar persistentu infekciju latentâ fâzç tâ bija
augstâka nekâ kontroles grupas indivîdiem. Bûtiski augstâks TNF- lîmenis konstatçts FM pacientiem ar plazmas virçmiju, persistentu
infekciju latentâ fâzç, salîdzinâjumâ ar pacientiem, kam netika konstatçta vîrusu infekcija. HHV-6A atrasts diviem pacientiem ar FM, bet
visiem pârçjiem FM pacientiem un visiem kontroles grupas indivîdiem atrasts HHV-6B. Bûtiski bieþâk konstatçta vienlaicîga HHV-6 un
HHV-7 infekcija, infekcijas aktivâcija, augstâka HHV-6 un HHV-7 slodze un augstâks TNF- ekspresijas lîmenis fibromialìijas
pacientiem, salîdzinot ar kontroles grupu, liecina par roseolovîrusu iespçjamo iesaisti slimîbas attîstîbâ.
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